Literature DB >> 15456267

Subtype selective substrates for histone deacetylases.

Birgit Heltweg1, Franck Dequiedt, Brett L Marshall, Carsten Brauch, Minoru Yoshida, Norikazu Nishino, Eric Verdin, Manfred Jung.   

Abstract

To probe the steric requirements for deacylation, we synthesized lysine-derived small molecule substrates and examined structure-reactivity relationships with various histone deacetylases. Rat liver, human HeLa, and human recombinant class I and II histone deacetylases (HDACs) as well as human recombinant NAD(+)-dependent SIRT1 (class III enzyme) were used in these studies. A benzyloxycarbonyl substituent on the alpha-amino group yielded the highest conversion rates. Replacing the epsilon-acetyl group with larger lipophilic acyl substituents led to a pronounced decrease in conversion by class I and II enzymes; the class III enzyme displayed a greater tolerance. Incubations with recombinant FLAG-tagged human HDACs 1, 3, and 6 showed a distinct subtype selectivity among small molecule substrates. The subtype selectivity of HDAC inhibitors could be predicted with these substrates and an easily obtainable mixture of HDAC subtypes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15456267     DOI: 10.1021/jm0497592

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  40 in total

1.  HDAC5 catalytic activity suppresses cardiomyocyte oxidative stress and NRF2 target gene expression.

Authors:  Tianjing Hu; Friederike C Schreiter; Rushita A Bagchi; Philip D Tatman; Mark Hannink; Timothy A McKinsey
Journal:  J Biol Chem       Date:  2019-04-08       Impact factor: 5.157

2.  Emergence of fibroblasts with a proinflammatory epigenetically altered phenotype in severe hypoxic pulmonary hypertension.

Authors:  Min Li; Suzette R Riddle; Maria G Frid; Karim C El Kasmi; Timothy A McKinsey; Ronald J Sokol; Derek Strassheim; Barbara Meyrick; Michael E Yeager; Amanda R Flockton; B Alexandre McKeon; Douglas D Lemon; Todd R Horn; Adil Anwar; Carlos Barajas; Kurt R Stenmark
Journal:  J Immunol       Date:  2011-08-03       Impact factor: 5.422

Review 3.  Isoform-selective histone deacetylase inhibitors.

Authors:  Anton V Bieliauskas; Mary Kay H Pflum
Journal:  Chem Soc Rev       Date:  2008-05-08       Impact factor: 54.564

Review 4.  Emerging roles for histone deacetylases in pulmonary hypertension and right ventricular remodeling (2013 Grover Conference series).

Authors:  Maria A Cavasin; Kurt R Stenmark; Timothy A McKinsey
Journal:  Pulm Circ       Date:  2015-03       Impact factor: 3.017

Review 5.  Cellular analysis of the action of epigenetic drugs and probes.

Authors:  Mirjam Hau; Fides Zenk; A Ganesan; Nicola Iovino; Manfred Jung
Journal:  Epigenetics       Date:  2017-01-10       Impact factor: 4.528

6.  Promiscuous actions of small molecule inhibitors of the protein kinase D-class IIa HDAC axis in striated muscle.

Authors:  Douglas D Lemon; Brooke C Harrison; Todd R Horn; Matthew S Stratton; Bradley S Ferguson; Michael F Wempe; Timothy A McKinsey
Journal:  FEBS Lett       Date:  2015-03-25       Impact factor: 4.124

7.  Inhibitors of the NAD(+)-Dependent Protein Desuccinylase and Demalonylase Sirt5.

Authors:  Benjamin Maurer; Tobias Rumpf; Michael Scharfe; Diana A Stolfa; Martin L Schmitt; Wenjuan He; Eric Verdin; Wolfgang Sippl; Manfred Jung
Journal:  ACS Med Chem Lett       Date:  2012-10-06       Impact factor: 4.345

8.  Histone deacetylase inhibitors (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory complex also activate HIV transcription.

Authors:  Koen Bartholomeeusen; Koh Fujinaga; Yanhui Xiang; B Matija Peterlin
Journal:  J Biol Chem       Date:  2013-03-28       Impact factor: 5.157

9.  Peptide arrays identify isoform-selective substrates for profiling endogenous lysine deacetylase activity.

Authors:  Zachary A Gurard-Levin; Kristopher A Kilian; Joohoon Kim; Katinka Bähr; Milan Mrksich
Journal:  ACS Chem Biol       Date:  2010-09-17       Impact factor: 5.100

10.  Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes.

Authors:  Angela Nebbioso; Fabio Manzo; Marco Miceli; Mariarosaria Conte; Lucrezia Manente; Alfonso Baldi; Antonio De Luca; Dante Rotili; Sergio Valente; Antonello Mai; Alessandro Usiello; Hinrich Gronemeyer; Lucia Altucci
Journal:  EMBO Rep       Date:  2009-06-05       Impact factor: 8.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.